Last reviewed · How we verify
NCT07467460: NEUROTECHNO
Precision Medicine and Neurodegenerative Diseases: Advanced Systems for the Diagnosis and Treatment of Parkinson's Disease and Alzheimer's Disease.
trial in PARKINSON DISEASE (Disorder) in 500 participants. Currently enrolling.
30 September 2028
Quick facts
| Lead sponsor | Neuromed IRCCS |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 500 |
| Start date | 17 February 2026 |
| Primary completion | 30 September 2028 |
| Estimated completion | 30 September 2028 |
| Sites | 1 location across Italy |
Conditions studied
- PARKINSON DISEASE (Disorder) — all drugs for PARKINSON DISEASE (Disorder) →
- Alzheimer s Disease — all drugs for Alzheimer s Disease →
- Diabete Type 2 — all drugs for Diabete Type 2 →
Sponsor
Neuromed IRCCS
Who can join
18 and older, any sex, with PARKINSON DISEASE (Disorder) or Alzheimer s Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In recent decades, advances in medicine have significantly improved both quality of life and life expectancy. However, these positive effects are also associated with a considerable increase in the prevalence of age-related diseases. Among these, Alzheimer's disease (AD), Parkinson's disease (PD), and type 2 diabetes (T2D) currently represent a major threat to human health. PD and AD are the most common neurodegenerative diseases in industrialized populations. In particular, AD accounts for 54% of all cases of dementia, with a prevalence of 4.4% among individuals over 65 years of age. PD has a prevalence of about 1% in people older than 60 years, reaching up to 4% in those over 80 years of age. AD and PD are highly disabling disorders with a slow but progressive course, caused by the degeneration and/or death of nerve cells. This results in impairments in the control of movement and balance, as in the case of PD, or in cognitive functioning, as in AD. To date, neither effective treatments nor early diagnostic tools are available to address these conditions in the initial phase of neurodegeneration. Likewise, there are no tools capable of monitoring disease progression and improving patients' adaptation to therapy. Moreover, although the association between T2D and the risk of PD and/or AD has long been recognized, these conditions were historically considered unrelated. Recent evidence from clinical and epidemiological studies suggests the existence of shared pathophysiological mechanisms associated with insulin resistance and persistent inflammation in several metabolically relevant tissues, such as adipose tissue and the brain. However, the mechanisms that increase the risk of PD and/or AD in individuals with T2D remain poorly understood. These data highlight how relevant these diseases are for the National Health System and demonstrate that they represent one of the most important priorities to be addressed, requiring substantial investments in both scientific research and early diagnostic strategies. Therefore, the present project proposal, which aims to develop new minimally invasive tools for the early prediction and monitoring of neurodegenerative diseases such as AD and PD, will help fill an important gap in the clinical and therapeutic management of these patients.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07467460
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for PARKINSON DISEASE (Disorder)
Currently open trials in the same condition.
- NCT07519096 — Steady Together Fall Prevention Program in the Home · NA · recruiting
- NCT07518290 — Remotely Supervised Home-based Transcranial Temporal Interference Stimulation on Motor Symptoms in Parkinson's Disease · NA · recruiting
- NCT07498296 — Adapting rHIRE and Sleep Monitoring in Parkinson's Disease · NA · recruiting
- NCT07478146 — Brief Title: Aerobic Training on Cerebrovascular Function, Cognition and Gait in Parkinson's Disease · NA · recruiting
- NCT07376278 — Predictors of Clinical Outcomes of Deep Brain Stimulation in Parkinson's Disease · recruiting
Other Neuromed IRCCS trials
Trials by the same sponsor.
- NCT06976983 — Transcranial Static Magnetic Stimulation (tSMS) in Huntington's Disease (HD) · NA · not yet recruiting
- NCT06900959 — Transcranial Static Field Stimulation (tSMS) and Transcranial Direct Current Stimulation (tDCS) for the Treatment of Neu · NA · not yet recruiting
- NCT05779449 — Targeting the Gut Dysbiosis to Treat Inflammation-driven Synaptopathy in MS · NA · recruiting
- NCT05784376 — The Southern Italian Children, Adolescents and PaRents COhort Study on Nutrition and Health · unknown
- NCT05173870 — Remote Monitoring to Prevent Frailty Progression in the Elderly · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07467460 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Neuromed IRCCS
- Last refreshed: 12 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07467460.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing